ライフサイエンスコーパス: platelet factor

1 ne production, fibrinogen binding sites, and platelet factor 3 activity.

2 proximately twice normal clotting times in a platelet factor 3 availability assay and, in a prothromb

3 us thrombosis with thrombocytopenia and anti-platelet factor 4 (anti-PF4) antibodies in individuals f

4 disorder associated with development of anti-platelet factor 4 (anti-PF4)/heparin autoantibodies.

5 t survival and decreased plasma thromboxane, platelet factor 4 (CXCL4), and IFN-gamma.

6 tion factor (M-CSF), and chemokines, such as platelet factor 4 (CXCL4).

7 lease of pro-inflammatory chemokines such as platelet factor 4 (CXCL4/PF4), are associated with perio

8 -reactive protein, beta-thromboglobulin, and platelet factor 4 (Hedges' gs = -0.23 to 0.02, ps >= 0.0

9 y antibodies against complexes between human platelet factor 4 (hPF4) and heparin.

10 two positively acting sequences in the human platelet factor 4 (hPF4) gene promoter that synergized t

11 ed a panel of HDPs and determined that human platelet factor 4 (hPF4) kills malaria parasites inside

12 Interactions between heparin, human platelet factor 4 (hPF4), antibodies to the hPF4/heparin

13 antimicrobial peptides from human platelets: platelet factor 4 (PF-4), RANTES, connective tissue acti

14 for megakaryocyte specific genes, c-mpl and platelet factor 4 (PF-4).

15 ing levels of the platelet-derived chemokine platelet factor 4 (PF4) (also known as CXCL4) were eleva

16 APC) improves survival in severe sepsis, and platelet factor 4 (PF4) accelerates APC generation in a

17 that monocytes complexed with surface-bound platelet factor 4 (PF4) activated by HIT antibodies cont

18 evels of the platelet-derived exerkine CXCL4/platelet factor 4 (PF4) ameliorates age-related regenera

19 T) is associated with antibodies that target platelet factor 4 (PF4) and are heparin-independent.

20 irected to large multimolecular complexes of platelet factor 4 (PF4) and heparin (H).

21 mediated by antibodies to complexes between platelet factor 4 (PF4) and heparin or cellular glycosam

22 antibodies that recognize complexes between platelet factor 4 (PF4) and heparin or glycosaminoglycan

23 botic disorder mediated by complexes between platelet factor 4 (PF4) and heparin or other polyanions,

24 therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin.

25 aused by antibodies that target complexes of platelet factor 4 (PF4) and heparin.

26 rcoagulable disorder caused by antibodies to platelet factor 4 (PF4) and heparin.

27 s composed of multiple molecules of cationic platelet factor 4 (PF4) and polyanions such as unfractio

28 VITT is caused by anti-platelet factor 4 (PF4) antibodies activating platelets

29 oss-linking of Fc gamma RIIA by anti-heparin/platelet factor 4 (PF4) antibodies is central to the pat

30 cytic niche and associated downregulation of platelet factor 4 (PF4) are pivotal mechanisms driving H

31 Additionally, platelet factor 4 (PF4) binds to bacteria and reduces th

32 arin therapy that is caused by antibodies to platelet factor 4 (PF4) complexed with heparin.

33 Although antibodies to heparin-platelet factor 4 (PF4) complexes are found in essential

34 uires detection of antibodies to the heparin/platelet factor 4 (PF4) complexes via enzyme-linked immu

35 The positively charged chemokine platelet factor 4 (PF4) forms immunogenic complexes with

36 Widely available HIT assays, such as the platelet factor 4 (PF4) heparin enzyme-linked immunosorb

37 activity by ICs containing IgG antibodies to platelet factor 4 (PF4) involved in heparin-induced thro

38 Platelet factor 4 (PF4) is a negative regulator of megak

39 Platelet factor 4 (PF4) is a negative regulator of megak

40 Here we discovered that chemokine platelet factor 4 (PF4) is a negative regulator of Th17

41 Platelet factor 4 (PF4) is an abundant chemokine that is

42 Platelet factor 4 (PF4) is an abundant platelet alpha-gr

43 Platelet factor 4 (PF4) is an abundant platelet alpha-gr

44 iles derived from these models revealed that platelet factor 4 (Pf4) is one of the main upregulated g

45 Platelet factor 4 (PF4) is produced by platelets with ro

46 The platelet-specific chemokine platelet factor 4 (PF4) is released in large amounts at

47 e estrogen receptor under the control of the platelet factor 4 (PF4) megakaryocyte-specific promoter.

48 mmunoglobulin G (IgG) antibodies, which bind platelet factor 4 (PF4) modified by polyanions, such as

49 components forming antigenic complexes with platelet factor 4 (PF4) on platelet surfaces to which an

50 oer et al. demonstrate that youth-associated platelet factor 4 (PF4) partially restores brain functio

51 e recombinase under the control of the mouse platelet factor 4 (Pf4) promoter generated megakaryocyte

52 Platelet factor 4 (PF4) serves as a lineage-specific mar

53 e ultralarge complexes (ULCs) of heparin and platelet factor 4 (PF4) tetramers.

54 xes between unfractionated heparin (UFH) and platelet factor 4 (PF4) that form over a narrow molar ra

55 tight electrostatic binding of the chemokine platelet factor 4 (PF4) to polyanions induces heparin-in

56 The chemokine platelet factor 4 (PF4) undergoes conformational changes

57 Testing for antibodies to platelet factor 4 (PF4) was positive in 22 patients (wit

58 Autoantibodies against platelet factor 4 (PF4) were detected in all patients, a

59 Association of platelet factor 4 (PF4) with heparin is a first step in

60 fic for complexes formed between heparin and platelet factor 4 (PF4), a basic protein found normally

61 Therefore, we investigated the effect of platelet factor 4 (PF4), a cationic protein released in

62 Platelet factor 4 (PF4), a platelet alpha-granule protei

63 We showed that platelet factor 4 (PF4), a platelet-associated chemokine

64 Platelet factor 4 (PF4), a platelet-derived CXC chemokin

65 Platelet factor 4 (PF4), a platelet-specific chemokine r

66 accination vectors versus SARS-CoV-2 bind to platelet factor 4 (PF4), a protein implicated in the pat

67 Platelet factor 4 (PF4), an abundant platelet alpha-gran

68 we used the megakaryocyte-specific promoters platelet factor 4 (PF4), and glycoprotein IIb (GPIIb) as

69 Immune complexes consisting of heparin, platelet factor 4 (PF4), and PF4/heparin-reactive Abs ar

70 Immune complexes consisting of heparin, platelet factor 4 (PF4), and PF4/heparin-reactive antibo

71 brain, alongside platelet concentration and platelet factor 4 (PF4), another neurogenic factor and a

72 sorder caused by immune complexes containing platelet factor 4 (PF4), antibodies to PF4 and heparin o

73 exes of platelet activation: platelet count, platelet factor 4 (PF4), beta-thromboglobulin (beta-TG),

74 genes tested, including GPIbalpha, GPIbbeta, platelet factor 4 (PF4), c-mpl, and p45 NF-E2.

75 Immune complexes consisting of platelet factor 4 (PF4), heparin, and PF4/heparin-reacti

76 by four essential components--heparin (Hep), platelet factor 4 (PF4), IgG antibodies against the Hep-

77 neutrophils and have a structure similar to platelet factor 4 (PF4), in which the first two cysteine

78 ion were observed in response to heparin and platelet factor 4 (PF4), indicating the heterogeneity of

79 pitalised controls and circulating levels of platelet factor 4 (PF4), soluble P-selectin (sP-selectin

80 ces in anticoagulant activity and binding to platelet factor 4 (PF4), which underlies heparin-induced

81 chemokine receptor 1 (Cx3cr1)-expressing and platelet factor 4 (Pf4)-expressing cells.

82 enzyme-linked immunosorbent assay to detect platelet factor 4 (PF4)-heparin antibodies and a modifie

83 We evaluated the presence of antibodies to platelet factor 4 (PF4)-polyanion complexes using a clin

84 Technically simple platelet factor 4 (PF4)-polyanion enzyme-linked immunoso

85 dies recognize complexes between heparin and platelet factor 4 (PF4).

86 ific for complexes consisting of heparin and platelet factor 4 (PF4).

87 platelet-activating antibodies (Abs) against platelet factor 4 (PF4).

88 telet-activating antibodies directed against platelet factor 4 (PF4).

89 hrombosis, and presence of autoantibodies to platelet factor 4 (PF4).

90 to production of autoantibodies recognizing platelet factor 4 (PF4).

91 dies that recognize an endogenous chemokine, platelet factor 4 (PF4).

92 tiation through the actions of the chemokine platelet factor 4 (PF4).

93 activation, which is further facilitated by platelet factor 4 (PF4).

94 , it forms complexes with positively charged platelet factor 4 (PF4).

95 Platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies and anti-PF4

96 performance of 3 immunoassays detecting anti-platelet factor 4 (PF4)/heparin antibodies, derived a di

97 (HIT) is caused by platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies.

98 ients with HIT develop autoantibodies to the platelet factor 4 (PF4)/heparin complex, which is termed

99 Antibodies specific for platelet factor 4 (PF4)/heparin complexes are the hallma

100 othrombotic disorder caused by antibodies to platelet factor 4 (PF4)/heparin complexes.

101 h patients tested strongly positive for anti-platelet factor 4 (PF4)/heparin immunoglobulin (Ig)G in

102 This study demonstrates that a human platelet factor 4 (PF4)/heparin-specific murine monoclon

103 g of the HIT-like monoclonal antibody KKO to platelet factor 4 (PF4)/heparin.

104 Affected patients test strongly positive in platelet factor 4 (PF4)/polyanion enzyme immunoassays (E

105 prochemotactic transcriptome and identified platelet factor 4 (Pf4, also known as CXCL4) as a periva

106 ility that immune complexes formed following platelet factor 4 (PF4/CXCL4) binding to anti-PF4 antibo

107 onstrate that the platelet-derived chemokine platelet factor 4 (PF4/CXCL4) stimulates VSMC injury res

108 and effectiveness of intravenous recombinant platelet factor 4 (rPF4) as an alternative to protamine

109 cretable form of the antiangiogenic protein, platelet factor 4 (sPF4).

110 s overexpression in transgenic mice (via the platelet factor 4 [PF4] promoter) on megakaryocyte devel

111 ting (IL-3) and growth-inhibitory (MIP-1 and platelet factor 4 [PF4]) cytokines, and extracellular ma

112 ration (glycoprotein [GP] Ibalpha, GPIX, and platelet factor 4 [PF4]), whereas GABPalpha-deficient me

113 iomarkers (fractalkine, platelet P-selectin, platelet factor 4 [PF4], and tumor necrosis factor-alpha

114 nfirmed HIT (4Ts score >/=4 points; positive platelet factor 4 [PF4]/heparin immunoassay, positive se

115 compared to other heparin-binding proteins (platelet factor 4 and antithrombin III), and diminished

116 rollary of these concepts is that disrupting platelet factor 4 and beta(2)GPI conformation (or ultral

117 and analyzed for sCD40L, interleukin-6, and platelet factor 4 and beta-thromboglobulin (markers of p

118 In contrast, platelet factor 4 and beta-thromboglobulin do not appear

119 HTTLPR l/l genotype had significantly higher platelet factor 4 and beta-thromboglobulin levels.

120 re more cognitively impaired, and had higher platelet factor 4 and beta-thromboglobulin levels; cardi

121 gin as other markers of platelet activation, platelet factor 4 and beta-thromboglobulin, were not inc

122 of CPB and was similar to that observed for platelet factor 4 and beta-thromboglobulin.

123 th antibodies to complexes that form between platelet factor 4 and glycosaminoglycan (GAG) side chain

124 ibodies to a multivalent antigen composed of platelet factor 4 and heparin.

125 tibodies against multimolecular complexes of platelet factor 4 and heparin.

126 Platelet-transported inflammatory mediators platelet factor 4 and serotonin accumulated in the graft

127 ibodies over 1 week sustained high levels of platelet factor 4 and serotonin.

128 ts demonstrated that P-selectin, fibrinogen, platelet factor 4 and vascular endothelial growth factor

129 Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccin

130 he case of VITT, also by platelet-activating platelet factor 4 antibodies reminiscent of heparin-indu

131 lts (including the results of tests for anti-platelet factor 4 antibodies where available), and radio

132 in association with platelet-activating anti-platelet factor 4 antibodies.

133 thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.

134 We now show that platelet factor 4 binds to monocytes and forms antigenic

135 n has improved in recent years, with heparin-platelet factor 4 complex as the culprit antigen in most

136 shown that antibodies reactive with heparin-platelet factor 4 complexes lead to FcgammaRIIA-mediated

137 se assay (SRA) and for antibodies to heparin/platelet factor 4 complexes with an ELISA.

138 7082, or TPCA-1) or by genetic manipulation (platelet factor 4 Cre:IKK-beta(flox/flox)), blocked SNAP

139 Platelet factor 4 did not correlate.

140 While the biological basis of platelet factor 4 expression has been pursued by others,

141 lasmic maturation (ie, glycoprotein GPIb and platelet factor 4 expression) and reduced the ability of

142 All 11 patients tested for the heparin-platelet factor 4 HIT antibody by enzyme-linked immunoso

143 transcription-induced release of sCD40L and platelet factor 4 in C57BL/6 mice.

144 Roles of IGFBP-1 and platelet factor 4 in HC.HA antiangiogenic action warrant

145 in the absence of clinical disease, such as platelet factor 4 in heparin-induced thrombocytopenia an

146 by determination of beta-thromboglobulin and platelet factor 4 in the supernatants, platelets bound t

147 0, monokine induced by gamma interferon, and platelet factor 4 inhibit epidermal growth factor (EGF)-

148 At this point, 50% of the platelet factor 4 is released, suggesting that half (app

149 Moreover, platelet factor 4 levels and platelet-derived extracellu

150 PLC-gamma2 and platelet factor 4 mRNA levels were normal.

151 (MIP-1beta), MIP-2, and KC (a member of the platelet factor 4 neutrophil chemoattractant family), as

152 kine C-X-C motif ligand 4 (CXCL4, also named platelet factor 4 or PF4) in the bone marrow, and we fou

153 (tTA), under the control of the MK-specific platelet factor 4 promoter (PF4-tTA-VP16).

154 or transgene expression to platelets using a platelet factor 4 promoter.

155 mbocytopenia antibody" attaches to a heparin-platelet factor 4 protein complex.

156 Serotonin, ADP/ATP, and platelet factor 4 release was profoundly affected in the

157 neration, platelet-derived growth factor and platelet factor 4 release, incorporation of thrombin int

158 hemokines, monokine induced by IFN-gamma and platelet factor 4 that also generate cAMP, inhibited EGF

159 GA6, and increased plasma concentrations of platelet factor 4 under basal conditions.

160 n PEDF and TSP-1 but did contain IGFBP-1 and platelet factor 4 while significantly suppressing neovas

161 Platelet factor 4(PF4), an abundant platelet secretory p

162 SERPINE1, CCL2) and anti-angiogenic factors (platelet factor 4) in vivo.

163 l expressed and secreted, RANTES) and CXCL4 (platelet factor 4) to the monocyte surface and endotheli

164 CL4L1, is a homologue of CXCL4 chemokine (or platelet factor 4) with potent anti-angiogenic activity

165 kines, PBP (platelet basic protein) and PF4 (platelet factor 4), are within 5.3 kilobases (kb) of eac

166 let and coagulation pathways, including PF4 (platelet factor 4), which may explain the prolonged thro

167 thrombocytopenia and antibodies against PF4 (platelet factor 4).

168 Platelet factor 4, a metric of platelet activation, was

169 subjects with severe asthma, whereas plasma platelet factor 4, a second platelet activation marker,

170 correlated with plasma levels of P-selectin, platelet factor 4, and platelet basic protein in the pop

171 ble factors serotonin (5-hydroxytryptamine), platelet factor 4, and platelet-activating factor, which

172 analyzed with ELISA for soluble P-selectin, platelet factor 4, and thrombospondin-1.

173 e Western blotting of factor V, prothrombin, platelet factor 4, antithrombin III, and fibrinogen.

174 Platelet factor 4, beta-thromboglobulin (betaTG), platel

175 The alpha-granule proteins platelet factor 4, beta-thromboglobulin, and platelet-de

176 role for platelets and their products (e.g., platelet factor 4, beta-thromboglobulin, RANTES, thrombo

177 0, monokine induced by interferon gamma, and platelet factor 4, limit fibroblast responsiveness to gr

178 osaccharides also exhibit low binding toward platelet factor 4, raising the possibility of preparing

179 myeloperoxidase (MPO)-DNA complexes (NETs), platelet factor 4, RANTES, and selected cytokines.

180 well as platelet-derived molecules including platelet factor 4, serotonin, P-selectin, and CD154 (CD4

181 The Platelet factor 4-Cre recombinase (Pf4-Cre) transgenic m

182 Platelet factor 4-Cre-mediated deletion of Slp-76 is suf

183 -induced platelet activation (HIPA) test and platelet factor 4-enhanced HIPA (PIPA).

184 tibodies show several similarities with anti-platelet factor 4-heparin antibodies and are a potential

185 he patients had high levels of antibodies to platelet factor 4-polyanion complexes; however, they had

186 ene for another platelet-specific chemokine, platelet factor 4.

187 , with more than 80% of them also containing platelet factor 4.

188 such as transforming growth factor beta1 or platelet factor 4.

189 llebrand factor (VWF), thrombospondin-1, and platelet factor 4.

190 :Ag) and propeptide (VWFpp), P-selectin, and platelet factor 4.

191 t is for GAG, its binding is not competed by platelet factor 4/CXCL4, and it is present on cells that

192 ted with a high incidence of IgG Abs against platelet factor 4/heparin (PF4/H) complexes by day 6 aft

193 a 4Ts score, rapid particle gel immunoassay (platelet factor 4/heparin [PF4/H]-PaGIA), and serotonin-

194 An immune-mediated response associated with platelet factor 4/heparin antibodies has been proposed a

195 Heparin-induced thrombocytopenia with platelet factor 4/heparin antibodies was diagnosed in a

196 An ELISA for anti-platelet factor 4/heparin antibodies was performed using

197 Platelet factor 4/heparin antibodies were quantified usi

198 on, and heparin-induced thrombocytopenia and platelet factor 4/heparin antibodies were rare.

199 ruary 2016 were analyzed for the presence of platelet factor 4/heparin antibodies.

200 rombocytopenia, and none (95% CI, 0%-4%) had platelet factor 4/heparin antibodies.

201 Antibodies to the platelet factor 4/heparin complex are a novel, independe

202 We postulated that antibodies to platelet factor 4/heparin complex might contribute to re

203 due primarily to IgG antibodies specific to platelet factor 4/heparin complexes (PF4/Hs) that activa

204 PRT/H Abs showed no cross-reactivity to platelet factor 4/heparin complexes, but were cross-reac

205 heparin therapy caused by antibodies against platelet factor 4/heparin complexes.

206 as diagnosed by the treating physician), and platelet factor 4/heparin IgG antibodies (optical densit

207 r a panel of 8 autoantibodies including anti-platelet factor 4/polyanion (anti-PF4/P), anti-phospholi

208 P483H contains the heparin-binding region of platelet factor-4 (PF-4) and a lysine-rich sequence for

209 evidence that changes in platelet-associated platelet factor-4 (PF-4) detect malignant growth across

210 rostate specific membrane antigen (PSMA) and platelet factor-4 (PF-4) in serum were captured on the a

211 , prostate specific membrane antigen (PSMA), platelet factor-4 (PF-4), and interleukin-6 (IL-6) simul

212 , prostate specific membrane antigen (PSMA), platelet factor-4 (PF-4), and interlukin-6 (IL-6).

213 g to provide direct evidence that tetrameric platelet factor-4 (PF4) and dimeric interleukin-8 (IL8),

214 Anti-platelet factor-4 (PF4) antibodies were observed in pati

215 ed, with the identification of antibodies to platelet factor-4 (PF4), but without previous heparin ex

216 xes of several human adenoviruses with human platelet factor-4 (PF4), coagulation factors FII (Prothr

217 -10, macrophage-derived chemokine [MDC], and platelet factor-4 [PF-4]) to be expressed by CD34(+) cel

218 Autoantibodies to platelet factor-4 are associated with catastrophic throm

219 parin-derived "Enoxaparin" showed comparable platelet factor-4 binding affinity, suggesting that it s

220 ogical criteria and by positive reaction for platelet factor-4 by Western blotting.

221 The presence of platelet factor-4 in the rinse samples was analyzed by W

222 al spatial expression of the chemokine CXCL4/platelet factor-4 marks the progression of fibrosis.

223 heparanase but a low affinity for off-target platelet factor-4 protein.

224 binding proteins, such as protamine sulfate, platelet factor-4, and beta-thromboglobulin.

225 , including neutrophil-activating protein-2, platelet factor-4, RANTES, and macrophage chemotactic pr

226 tment with rhMIP-1 beta or rhRANTES, but not platelet factor-4, resulted in improved thymic homing of

227 otein convertase subtilisin/kexin type 9 and platelet factor-4, whereas they had a minimal inhibitory

228 wth-related protein-alpha (Gro-alpha) and to platelet factor-4-M2 (PF4-M2), an N-terminal chimera of

229 wth factor-2 binding but a weak affinity for platelet factor-4.

230 hlights the significant influence that serum/platelet factors can have on virus binding and identifie

231 Whether platelet factor H is acquired by passive adsorption from

232 secretion of [3H]-5HT (dense core granules), platelet factor IV (alpha granules), or hexosaminidase (

233 trauma, and acquired abnormal coagulation or platelet factors (p < .05).

234 crophage inflammatory protein (MIP)-1 alpha, platelet factor (PF) 4, interferon inducible protein (IP

235 kDa proteins were subsequently identified as platelet factor (PF)4 and connective tissue activating p

236 Platelet factors that were associated with improved plat

237 rauma with exposure to high serum levels and platelet factors, these unexpected findings highlight a

238 Here we show that platelet factors transfer the benefits of young blood to

239 Measurement of platelet factor V (FV) levels in 7 F5F8D patients (4 wit

240 diathesis appears to reflect the absence of platelet factor V activity.

241 These include platelet factor V and, surprisingly, plasma tissue facto

242 include mild thrombocytopenia and defective platelet factor V.

243 sts may in addition be the result of reduced platelet factor Va expression and modulation of the plat

244 Plasma and platelet factor Va represent different substrates for ac

245 These animals had platelet factor VIII levels equivalent to 3% to 9% plasm

246 y led to platelet aggregation and release of platelet factors which would trigger the proliferation o

247 he factor is abolished by treating the crude platelet factor with the polyphosphate-degrading enzyme

248 r collagen at various concentrations exposed platelet factor XI and PAC1 antibody binding in parallel

249 ver, the site of synthesis and the nature of platelet factor XI are not known.

250 atelets expressed approximately 40% of total platelet factor XI but no PAC1 binding sites.

251 secretion, because ADP and collagen exposed platelet factor XI but no S12 binding sites.

252 Thus, platelet factor XI is an alternative splicing product of

253 Platelet factor XI is an alternatively spliced product o

254 Platelet factor XI is associated with the platelet plasm

255 Thus, functionally active platelet factor XI is differentially expressed on platel

256 Enhanced membrane exposure of platelet factor XI is independent of alpha-granule secre

257 he outer surface of growing thrombi, such as platelet factor XI or blood-borne TF, appears essential

258 utive and activation-dependent expression of platelet factor XI.

259 B subunit of factor XIII since placental or platelet factor XIII (A2), which does not contain B subu